HTR2B and attention deficit-hyperactivity disorder: Its pharmacological profile includes moderate norepinephrine reuptake inhibition with additional serotonergic activity, particularly 5-HT2C agonism and 5-HT2B antagonism, which supported its repurposing as an extended-release formulation for ADHD.